Dishman Carbogen Amcis

Dishman Carbogen Amcis Limited is a fully integrated, global outsourcing partner for the pharmaceutical and biopharmaceutical industries, offering a comprehensive suite of services spanning from process development to commercial manufacturing of Active Pharmaceutical Ingredients (APIs). Headquartered in Ahmedabad, India, with major operational hubs in Switzerland (Carbogen Amcis), the UK, France, and China, the company provides a unique east-west hybrid model that blends European technological excellence with Indian manufacturing scale and cost-efficiency.

Dishman Carbogen Amcis is globally recognized for its unparalleled expertise in handling Highly Potent Active Pharmaceutical Ingredients (HPAPIs). They operate cutting-edge high-containment facilities capable of safely manufacturing highly toxic compounds, such as oncology drugs and the cytotoxic payloads used in Antibody-Drug Conjugates (ADCs), down to exposure levels of less than 1 µg/m³.

Beyond HPAPIs, the company excels in complex organic synthesis, biocatalysis, and the development of complex generic APIs and intermediates (such as Vitamin D analogues and cholesterol products). Their Swiss division, Carbogen Amcis, acts as a premier boutique CDMO, closely collaborating with early-stage biotech firms to rapidly advance molecules through clinical trials.

Once these molecules reach commercial viability, production can be seamlessly transferred to Dishman’s massive GMP facilities in India. This integrated capability, combined with a stellar regulatory track record with the US FDA, Swissmedic, and other major authorities, makes Dishman Carbogen Amcis a vital engine for global pharmaceutical innovation and oncology drug supply.